Truist Beefs Up Price Target On HCA Healthcare

Truist raised the price target on HCA Healthcare Inc HCA to $310 (implying 16% upside) from $290 and kept a Buy rating as part of a broader research note on Healthcare Services. 

  • Analyst David MacDonald is positive on several names in the group thanks to their "sound fundamentals, brisk core demand drivers, a relatively benign regulatory backdrop, and the ongoing move towards value-based care." 
  • MacDonald adds that strong free cash flow and financial flexibility across much of the sector should fuel continued strategic M&A, and he sees valuation risk-rewards in the group as "attractive."
  • Recently, JPMorgan analyst Lisa Gill downgraded HCA Healthcare to Neutral from Overweight with an unchanged price target of $270 in conjunction with her 2022 outlook. 
  • While HCA is well positioned on a long-term basis, other managed care names have more near-term upside, Gill notes.
  • The analyst believes HCA is the best-positioned hospital operator in the U.S. but believes other companies she covers offer more significant near-term upside. 
  • She expects "modest" EBITDA growth in 2022, reflecting labor pressures and the roll-off of temporary COVID-19-related tailwinds.
  • Price Action: HCA shares are up 2.69% at $267.27 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorNewsHealth CarePrice TargetReiterationAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!